{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:11:51Z","timestamp":1788455511537,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["2024ER051701"],"award-info":[{"award-number":["2024ER051701"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijgc.2026.104652","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:42:45Z","timestamp":1774021365000},"page":"104652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of primary treatment modality and programmed death-ligand 1 expression with survival outcomes in locally advanced human papillomavirus\u2013independent endocervical adenocarcinoma"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-2079","authenticated-orcid":false,"given":"Hyunji","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeran","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Hoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-9436","authenticated-orcid":false,"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104652_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104652_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4143\/crt.2022.128","article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019","volume":"54","author":"Kang","year":"2022","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5858\/arpa.2018-0259-RA","article-title":"Cervical adenocarcinomas: a heterogeneous group of tumors with variable etiologies and clinical outcomes","volume":"143","author":"Hodgson","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104652_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/gyno.2000.5826","article-title":"The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study","volume":"78","author":"Smith","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"49","key":"10.1016\/j.ijgc.2026.104652_bib5","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1016\/j.vaccine.2011.09.115","article-title":"Cervical adenocarcinoma: moving towards better prevention","volume":"29","author":"Seoud","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib6","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.3802\/jgo.2019.30.e38","article-title":"Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999\u20132015","volume":"30","author":"Lim","year":"2019","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/his.13995","article-title":"Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification","volume":"76","author":"Park","year":"2020","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/PAS.0000000000001095","article-title":"International endocervical adenocarcinoma criteria and classification: validation and interobserver reproducibility","volume":"43","author":"Hodgson","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104652_bib9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1055\/a-1545-4279","article-title":"2020 WHO classification of female genital tumors","volume":"81","author":"H\u00f6hn","year":"2021","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2023.03.048","article-title":"The updated World Health Organization classification better predicts survival in patients with endocervical adenocarcinoma (KROG 20\u201307)","volume":"117","author":"Cho","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104652_bib11","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e71","article-title":"Predicting prognosis according to the updated WHO classification in patients with endocervical adenocarcinoma treated with surgery and radiotherapy","volume":"33","author":"Cho","year":"2022","journal-title":"J Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104652_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.21873\/cgp.20219","article-title":"Clinicopathological and molecular differences between gastric-type mucinous carcinoma and usual-type endocervical adenocarcinoma of the uterine cervix","volume":"17","author":"Jung","year":"2020","journal-title":"Cancer Genomics Proteomics"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104652_bib13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jjco\/hyae019","article-title":"Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions","volume":"54","author":"Nishio","year":"2024","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104652_bib14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/PAS.0000000000000532","article-title":"Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis","volume":"39","author":"Karamurzin","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2019.01.022","article-title":"Analysis of gastric-type mucinous carcinoma of the uterine cervix \u2014 an aggressive tumor with a poor prognosis: a multi-institutional study","volume":"153","author":"Nishio","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/igc.0000000000001145","article-title":"Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the Sankai gynecology study group","volume":"28","author":"Kojima","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104652_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ygyno.2022.10.003","article-title":"Gastric-type adenocarcinoma of the cervix: clinical outcomes and genomic drivers","volume":"167","author":"Ehmann","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104652_bib18","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e92","article-title":"Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study","volume":"36","author":"Baek","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ijgo.70028","article-title":"Prognostic impact of primary surgery in human papillomavirus-independent, advanced or metastatic endocervical adenocarcinoma: a bi-institutional retrospective study","volume":"170","author":"Seo","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104652_bib20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/his.14435","article-title":"PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma","volume":"79","author":"Song","year":"2021","journal-title":"Histopathology."},{"issue":"2","key":"10.1016\/j.ijgc.2026.104652_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/his.14552","article-title":"Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance","volume":"80","author":"Chen","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cjp2.345","article-title":"Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance","volume":"10","author":"Sun","year":"2024","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13000-025-01666-7","article-title":"Clinical pathological and molecular features of 100 patients with gastric-type cervical adenocarcinoma","volume":"20","author":"Gao","year":"2025","journal-title":"Diagn Pathol"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104652_bib24","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.3390\/ijms26157469","article-title":"A comparative analysis of usual- and gastric-type cervical adenocarcinoma in a Japanese population reveals distinct clinicopathological and molecular features with prognostic and therapeutic insights","volume":"26","author":"Zahan","year":"2025","journal-title":"Int J Mol Sci."},{"issue":"20","key":"10.1016\/j.ijgc.2026.104652_bib25","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"10434","key":"10.1016\/j.ijgc.2026.104652_bib26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104652_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:06:10Z","timestamp":1777885570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1048891X26001830"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104652","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of primary treatment modality and programmed death-ligand 1 expression with survival outcomes in locally advanced human papillomavirus\u2013independent endocervical adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104652"}}